Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis

Pediatric Blood and Cancer

Volumn 60, Issue 1, 2013, Pages 82-87

  Choi, Soo Han ^a   Lee, Soo Youn ^a   Hwang, Ji Young ^b,c   Lee, Soo Hyun ^a   Yoo, Keon Hee ^a   Sung, Ki Woong ^a   Koo, Hong Hoe ^a   Kim, Yae Jean ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c BK21 Plus NBM Global Research Center for Regenerative Medicine   (South Korea)

Author keywords

Child; Invasive aspergillosis; Therapeutic drug monitoring; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CYCLOSPORIN; ITRACONAZOLE; MIDAZOLAM; PHENYTOIN; PROTON PUMP INHIBITOR; TACROLIMUS; VORICONAZOLE;

ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHILDHOOD CANCER; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; INFANT; INVASIVE ASPERGILLOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; STEADY STATE;

ADOLESCENT; AGE FACTORS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; INFANT; MALE; PYRIMIDINES; TRIAZOLES;

EID: 84870191672     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24262     Document Type: Article

References (27)

1. Steinbach WJ. Pediatric invasive aspergillosis. Pediatr Infect Dis J 2010; 29: 964-965.
2. Lat A, Thompson GR III. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011; 4: 43-53.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
4. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
5. Hussaini T, Ruping MJ, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011; 31: 214-225.
6. Pasqualotto AC, Xavier MO, Andreolla HF, et al. Voriconazole therapeutic drug monitoring: Focus on safety. Expert Opin Drug Saf 2010; 9: 125-137.
7. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54: 4116-4123.
8. Miyakis S, van Hal SJ, Ray J, et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-933.
9. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-944.
10. Smith J, Andes D. Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167-172.
11. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
12. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42: 1859-1864.
13. Pasqualotto AC, Shah M, Wynn R, et al. Voriconazole plasma monitoring. Arch Dis Child 2008; 93: 578-581.
14. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-411.
15. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683.
16. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
17. Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: e1286-e1294.
18. Crassard N, Hadden H, Piens MA, et al. Invasive aspergillosis in a paediatric haematology department: A 15-year review. Mycoses 2008; 51: 109-116.
19. Rubio PM, Sevilla J, Gonzalez-Vicent M, et al. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study. J Pediatr Hematol Oncol 2009; 31: 642-646.
20. Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study. J Antimicrob Chemother 2012; 67: 700-706.
21. Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer 2010; 54: 1050-1052.
22. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172.
23. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553.
24. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50: 27-36.
25. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31: 731-741.
26. Moriyama B, Elinoff J, Danner RL, et al. Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother 2009; 53: 1712-1714.
27. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-1572.